Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice Correlations With Plaques, Tangles, and Oligomeric Species

Author

López González, Irene

Schlüter, Agatha

Aso, Ester

García Esparcia, Paula

Ansoleaga, Belen

Llorens, Franc

Moreno, Jesús

Fuso, Andrea

Portero Otín, Manuel

Pamplona Gras, Reinald

Pujol, Aurora

Ferrer, Isidre

Carmona, Margarita

Publication date

2016-11-10T08:41:48Z

2025-01-01

2015



Abstract

To understand neuroinflammation-related gene regulation during normal aging and in sporadic Alzheimer disease (sAD), we performed functional genomics analysis and analyzed messenger RNA (mRNA) expression by quantitative reverse transcription–polymerase chain reaction of 22 genes involved in neuroinflammation-like responses in the cerebral cortex of wild-type and APP/PS1 transgenic mice. For direct comparisons, mRNA expression of 18 of the same genes was then analyzed in the entorhinal cortex, orbitofrontal cortex, and frontal cortex area 8 of middle-aged human subjects lacking Alzheimer disease–related pathology and in older subjects with sAD pathology covering Stages I–II/0(A), III–IV/A–B, and V–VI/C of Braak and Braak classification. Modifications of cytokine and immune mediator mRNA expression were found with normal aging in wild-type mice and in middle-aged individuals and patients with early stages of sAD-related pathology; these were accompanied by increased protein expression of certain mediators in ramified microglia. In APP/PS1 mice, inflammatory changes coincided with β-amyloid (Aβ) deposition; increased levels of soluble oligomers paralleled the modified mRNA expression of cytokines and mediators in wild-type mice. In patients with sAD, regulation was stage- and region-dependent and not merely acceleration and exacerbation of mRNA regulation with aging. Gene regulation at first stages of AD was not related to hyperphosphorylated tau deposition in neurofibrillary tangles, Aβ plaque burden, concentration of Aβ1–40 (Aβ40) and Aβ1–42 (Aβ42), or fibrillar Aβ linked to membranes but rather to increased levels of soluble oligomers. Thus, species differences and region- and stage-dependent inflammatory responses in sAD, particularly at the initial stages, indicate the need to identify new anti-inflammatory compounds with specific molecular therapeutic targets. Key Words


This study was funded by the Seventh Framework Program of the European Commission (Grant No. 278486 [DEVELAGE project] to Isidre Ferrer and Andrea Fuso) and by the Spanish Ministry of Health, Instituto Carlos III (Fondo de Investigacio´n Sanitaria [FIS] PI1100968, FIS PI14/00757, and CIBERNED project BESAD-P to Isidre Ferrer; FIS PI 11/1532 to Manuel Portero-Otin; and Spanish Ministry of Economy and Competitiveness Grant Nos. BFU2009-11879/BFI and PI1300584 to Reinald Pamplona). Agatha Schlu¨ter was supported by FIS ECA07/055.

Document Type

article
publishedVersion

Language

English

Subjects and keywords

Beta-amyloid; Cytokines,; Genomics; Neuroinflammation

Publisher

Oxford Journals

Related items

info:eu-repo/grantAgreement/MICINN//BFU2009-11879/ES/Efecto Del Envejecimiento Y De La Restriccion De Metionina Sobre La Vulnerabilidad Neuronal Al Estres Oxidativo En Diferentes Regiones Del Sistema Nervioso Central/

Reproducció del document publicat a https://doi.org/10.1097/NEN.0000000000000176

Journal of Neuropathology & Experimental Neurology, 2015, vol. 74, núm. 4, p. 319-344

info:eu-repo/grantAgreement/EC/FP7/278486

Rights

(c) American Association of Neuropathologists, Inc., 2015

This item appears in the following Collection(s)